In this regard, the BRAF/MEK/ERK pathway represents an ideal candidate for targeting both oncogene and metabolism of certain types of tumors, especially melanomas [98, 106–109], or may work successfully as a combinatorial regimen with other anticancer drugs [109, 129, 130]. The gene discussed is MAPK1; the disease is melanoma.